Benlysta Decision Likely To Be Delayed By Negotiations On Labeling
Executive Summary
The Arthritis Advisory Committee's call for FDA to tailor labeling to restrict claims of efficacy to the clinical trial population for Human Genome Sciences' lupus drug Benlysta (belimumab) will likely push a decision on the drug beyond its Dec. 9 user fee date.
You may also be interested in...
Benlysta In GSK’s Hands: A Slow-but-steady Launch, Or A Dud?
With GlaxoSmithKline and Human Genome Sciences agreeing to a merger July 16, the key question for the multinational pharma becomes what it will do to strengthen sales for Benlysta, a lupus drug launched in 2011 that has fallen short of bullish commercial expectations.
HGSI/GSK's Benlysta Gets BLySfully Clean Labeling, Escaping Feared Restrictions
The indication is notable for what it does not contain, which is language specifically excluding African Americans or patients with severe active lupus nephritis or severe central nervous system lupus.
HGSI/GSK's Benlysta Gets BLySfully Clean Labeling, Escaping Feared Restrictions
The indication is notable for what it does not contain, which is language specifically excluding African Americans or patients with severe active lupus nephritis or severe central nervous system lupus.